Comparative Pharmacology
Head-to-head clinical analysis: GO EVAC versus PLEGISOL IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GO EVAC versus PLEGISOL IN PLASTIC CONTAINER.
GO-EVAC vs PLEGISOL IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Promotes gastrointestinal motility by acting as a stimulant laxative, likely through direct irritation of the colonic mucosa and possibly via local effects on enteric neurons.
PLEGISOL is an extracellular-type crystalloid cardioplegic solution used for myocardial protection during cardiac surgery. Its mechanism involves inducing rapid cardiac arrest by high potassium concentration (depolarizing arrest), reducing myocardial oxygen demand, and providing buffering capacity via tromethamine to maintain pH. The solution also contains magnesium to stabilize membranes and mannitol as an osmotic agent to reduce edema.
10 mg orally once daily, with or without food.
Administered as an intraperitoneal infusion for organ preservation. Typical adult dose: 2.5-3.0 liters for kidney, 2.5-3.0 liters for liver, 3.0-4.0 liters for pancreas, single dose prior to procurement.
None Documented
None Documented
4.5-6 hours in healthy volunteers; prolonged to 10-14 hours in elderly patients and those with moderate renal impairment (CrCl 30-50 mL/min).
Not applicable; Plegisol is not a systemically active drug. Its cardioplegic effect is immediate upon perfusion into coronary arteries and dissipates upon reperfusion. The solution's components have endogenous half-lives (e.g., potassium: 1-1.5 h in plasma), but this is not clinically relevant for the product.
Primarily renal; approximately 60% eliminated unchanged in urine within 24 hours, with 20% as metabolites. Biliary/fecal excretion accounts for 15-20%, and the remainder is metabolized via glucuronidation.
Plegisol is an extracellular cardioplegic solution; its components (electrolytes and calcium) are not metabolized. Elimination of infused volume occurs primarily via renal excretion (approx. 95%) as unchanged water and electrolytes; minor biliary/fecal elimination (<5%) accounts for negligible electrolyte loss.
Category C
Category C
Osmotic Laxative
Osmotic Laxative